Josh Oliver

Tight End

Age: 27
Free Agency: 2026 (Void)
Accrued Seasons: 5
  • 2024 Salary Cap Charge: $6,174,000 (2.36% of cap)
  • 2024 Cash Payout: $4,750,000 (2.36% of spending)
  • 2024 Cash to Cap Ratio: 0.77
  • Contract Value: $21,000,000 ($7,000,000 APY)
  • Fully Guaranteed Money: $8,200,000
  • Contract Ranking: 18/157 at TE

Current Contract

(UFA, signed 2023)
(📝: indicates contract trigger occuring during that year)
YearAgeBase SalaryProrated Signing BonusWorkout BonusGuaranteed SalaryCap
Number
Cap %
Dead Money & Cap Savings
202326$1,080,000$1,424,000$50,000$1,080,000$2,554,0001.2%
2024 📝
March 16: $2.5 million of salary is guaranteed
27$4,700,000$1,424,000$50,000$2,500,000$6,174,0002.4%
202528$7,950,000$1,424,000$50,000$0$9,424,0003.6%
2026 📝
February 20: Contract voids
29Void$1,424,000VoidVoid$2,848,0001.0%
202730Void$1,424,000VoidVoid$00.0%
Total$13,730,000$7,120,000$150,000$3,580,000$21,000,000

Contract Notes

Josh Oliver signed a three year, $21 million contract with the Vikings. $10.7 million is guaranteed of which $8.2 million is fully guaranteed at signing. If on the roster on the 3rd day of the 2024 league year another $2.5 million is guaranteed. There are up to $6 million in incentives and escalators.

Cash Flows

- fully earned money
- unearned or partially earned money
$7M
$14M
$21M
202320242025
Cash Due$8,250,000$4,750,000$8,000,000
Running Cash$8,250,000$13,000,000$21,000,000
Career Earnings: $12,459,550
Career APY: $2,491,910
Potential Earnings: $25,209,550
Total Guarantees: $10,423,048
Largest Cash Payment: $8,250,000 (2023)
Largest Cap Number: $9,424,000 (2025)

Contract History

TeamContract TypeStatusYear SignedYrsTotalAPYGuaranteesAmount Earned% EarnedEffective APY
JaguarsDraftedTraded20194$4,250,844$1,062,711$1,111,524$2,253,45053.0%$1,126,725
RavensDraftedExpired20194$4,250,844$1,062,711$1,111,524$1,956,10046.0%$978,050
VikingsUFAActive20233$21,000,000$7,000,000$8,200,000$8,250,00039.3%$8,250,000
Earnings By Team
TeamYrsSalaryAPYPaid on Cap% Paid on CapPaid as Dead Money% Paid as Dead Money
Jaguars2$2,253,450$1,126,725$1,697,6880.0%$555,7620.0%
Ravens2$1,956,100$978,050$1,956,1000.0%$00.0%
Vikings1$8,250,000$8,250,000$2,554,0000.0%$00.0%

Season History

YearTeamBase SalaryProrated BonusWorkout BonusGuaranteed SalaryCap
Number
Cap %Cash Paid
2019Jaguars$495,000$277,881$0$0$731,5870.4%$1,565,230
2020Jaguars$688,220$277,881$0$0$966,1010.5%$688,220
2021Ravens$881,440$0$0$0$881,4400.5%$881,440
2022Ravens$1,074,660$0$0$0$1,074,6600.5%$1,074,660
2023Vikings$1,080,000$1,424,000$50,000$1,080,000$2,554,0001.2%$8,250,000
2024Vikings$4,700,000$1,424,000$50,000$2,500,000$6,174,0002.4%$4,750,000
2025Vikings$7,950,000$1,424,000$50,000$0$9,424,0003.6%$8,000,000
2026Vikings$0$1,424,000$0$0$2,848,0001.0%$0
2027Vikings$0$1,424,000$0$0$00.0%$0
Total$16,869,320$7,675,762$150,000$3,580,000$24,653,788$25,209,550
Dead Money History
TeamYearCap ChargeCash Paid
Jaguars2021$555,762$0
Total$555,762$0

Statistics

YearGames PlayedGames InactiveSnapsRushingReceivingFumbles
InjuredHealthyOffenseSpecialAttYardsAvgTDRecYardsAvgTDTotalLost
2019412010.7%0.0%000.00000.0000
2021140112.5%18.8%000.009667.3000
2022160045.0%28.3%000.001414910.6200
2023170041.6%34.7%000.00222139.7200

Valuation Diamond

The diamond is a scatterplot graph that visualizes the relation of the player's APY (in green) and performance (in blue, as measured by OTC's Valuations) to the rest of the league at his position. To understand how to read the diamond, read this explainer.

OTC ValuationAPY
Regular$4,228,000$7,000,000
Injury Adjusted$4,228,000$7,000,000
test
OTC Valuation $2M $4M $6M $8M $10M APY $2.8M $5.7M $8.5M $11.3M $14.2M $6,604,000 $8,227,624

Weekly Valuation Trends

The chart below illustrates the trend of the player's weekly OTC Valuations (in blue) from the most recent season, using APY (in green) and, if applicable, cash that is due to the player in the next season (in red) as benchmarks. Weeks not plotted indicate that the player was inactive or on a bye.

To see interactive and more in-depth use of OTC Valuation data, subscribe to OTC Premium.